WO2022232629A3 - Polyphenol compositions having improved bioavailability - Google Patents

Polyphenol compositions having improved bioavailability Download PDF

Info

Publication number
WO2022232629A3
WO2022232629A3 PCT/US2022/027115 US2022027115W WO2022232629A3 WO 2022232629 A3 WO2022232629 A3 WO 2022232629A3 US 2022027115 W US2022027115 W US 2022027115W WO 2022232629 A3 WO2022232629 A3 WO 2022232629A3
Authority
WO
WIPO (PCT)
Prior art keywords
polyphenol
compositions
improved bioavailability
polyphenol compositions
tri
Prior art date
Application number
PCT/US2022/027115
Other languages
French (fr)
Other versions
WO2022232629A2 (en
Inventor
John GILDEA
Original Assignee
Epiceutical Labs Llc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epiceutical Labs Llc. filed Critical Epiceutical Labs Llc.
Priority to EP22796880.7A priority Critical patent/EP4329813A2/en
Priority to CA3215173A priority patent/CA3215173A1/en
Priority to CN202280031251.9A priority patent/CN117222432A/en
Publication of WO2022232629A2 publication Critical patent/WO2022232629A2/en
Publication of WO2022232629A3 publication Critical patent/WO2022232629A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L35/00—Food or foodstuffs not provided for in groups A23L5/00 – A23L33/00; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compositions and tri-molecular complexes of polyphenol-polysaccharide-protein are provided wherein the polyphenol is non-covalently complexed with covalently-linked polysaccharide and protein. The bioavailability of the polyphenol is such compositions is significantly increased in the disclosed compositions and tri-molecular complexes. Such compositions may be used to deliver high concentrations of the polyphenol for treating various conditions and diseases.
PCT/US2022/027115 2021-04-30 2022-04-29 Polyphenol compositions having improved bioavailability WO2022232629A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP22796880.7A EP4329813A2 (en) 2021-04-30 2022-04-29 Polyphenol compositions having improved bioavailability
CA3215173A CA3215173A1 (en) 2021-04-30 2022-04-29 Polyphenol compositions having improved bioavailability
CN202280031251.9A CN117222432A (en) 2021-04-30 2022-04-29 Polyphenol composition with improved bioavailability

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163182721P 2021-04-30 2021-04-30
US63/182,721 2021-04-30

Publications (2)

Publication Number Publication Date
WO2022232629A2 WO2022232629A2 (en) 2022-11-03
WO2022232629A3 true WO2022232629A3 (en) 2022-12-01

Family

ID=83848872

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/027115 WO2022232629A2 (en) 2021-04-30 2022-04-29 Polyphenol compositions having improved bioavailability

Country Status (4)

Country Link
EP (1) EP4329813A2 (en)
CN (1) CN117222432A (en)
CA (1) CA3215173A1 (en)
WO (1) WO2022232629A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116210803A (en) * 2023-02-06 2023-06-06 东北农业大学 Method for improving stability of isolated soy protein by compounding with polyphenol
CN116686985A (en) * 2023-06-20 2023-09-05 南昌大学第二附属医院 Processing method of colon controlled release fruit and vegetable gel beads

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200254104A1 (en) * 2019-02-11 2020-08-13 John CHANCEY Methods of making and using phytocannabinoids complexed with a protein, peptide, amino acid, polysaccharide, disacchride, or monosaccharide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200254104A1 (en) * 2019-02-11 2020-08-13 John CHANCEY Methods of making and using phytocannabinoids complexed with a protein, peptide, amino acid, polysaccharide, disacchride, or monosaccharide

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHUANG CHIH-CHIEH, YE AIQIAN, ANEMA SKELTE G., LOVEDAY SIMON M.: "Concentrated Pickering emulsions stabilised by hemp globulin–caseinate nanoparticles: tuning the rheological properties by adjusting the hemp globulin : caseinate ratio", FOOD & FUNCTION, R S C PUBLICATIONS, GB, vol. 11, no. 11, 18 November 2020 (2020-11-18), GB , pages 10193 - 10204, XP093012124, ISSN: 2042-6496, DOI: 10.1039/D0FO01745K *
DATABASE GenBank ANONYMOUS : "hypothetical protein F8388_010822 [Cannabis sativa]", XP093012125, retrieved from NCBI *
MADL ET AL.: "Presentation of BMP-2 Mimicking Peptides in 3D Hydrogels Directs Cell Fate Commitment in Osteoblasts and Mesenchymal Stem Cells", BIOMACROMOLECULES, vol. 15, no. 2, 10 February 2014 (2014-02-10), pages 445 - 455, XP055809420, DOI: 10.1021/bm401726u *
MATHEW ET AL.: "Antiviral potential of curcumin", JOURNAL OF FUNCTIONAL FOODS, vol. 40, January 2018 (2018-01-01), pages 692 - 699, XP085357998, DOI: 10.1016/j.jff.2017.12.017 *

Also Published As

Publication number Publication date
CA3215173A1 (en) 2022-11-03
WO2022232629A2 (en) 2022-11-03
CN117222432A (en) 2023-12-12
EP4329813A2 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
WO2022232629A3 (en) Polyphenol compositions having improved bioavailability
WO2019222112A8 (en) Mcl-1 inhibitors
WO2022060836A8 (en) Indole derivatives as ras inhibitors in the treatment of cancer
MX2022004513A (en) Bicyclic heterocycles as fgfr inhibitors.
MX2019013690A (en) Cyclodextrin protein drug conjugates.
MX2022010512A (en) Bcl-2 protein inhibitors.
MX2022000310A (en) Bcl-2 protein inhibitors.
MX2022009596A (en) Anti-ror1 antibodies and compositions.
BR112023022819A2 (en) COMPOUNDS, PHARMACEUTICAL COMPOSITION, CONJUGATES AND METHODS FOR TREATING CANCER IN A SUBJECT, FOR TREATING A DISORDER AND FOR INHIBITING A RAS PROTEIN IN A CELL
EA202193111A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
MX2022010977A (en) Inhibitors of egfr, kras, braf, and other targets and use of the same.
MX2022010975A (en) Inhibitors of egfr, kras, braf, and other targets and use of the same.
WO2018183370A3 (en) Kdm4 inhibitors
EA201991192A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CANCER
WO2022235870A8 (en) Ras inhibitors for the treatment of cancer
WO2022082073A3 (en) Compositions and methods for muc18 targeting
WO2023081830A3 (en) Compositions and treatments with nirogacestat
CR20230282A (en) Indole derivatives useful in treating conditions associated with cgas
MX2022000308A (en) Nanoparticle formulation of bcl-2 inhibitor.
CL2022003713A1 (en) Methods and compositions for use in glued-wood products
WO2021161023A8 (en) Compounds useful in inhibiting ketohexokinase and methods of making and using the same
WO2022038417A3 (en) Modified il-18 polypeptides and uses thereof
WO2021247688A8 (en) Nanobody (vhh) conjugates and uses there of
MX2022014909A (en) Treatment of cancer.
MX2022010859A (en) Undenatured type ii collagen in animal food and treats.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 3215173

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 202280031251.9

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2022796880

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022796880

Country of ref document: EP

Effective date: 20231130

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22796880

Country of ref document: EP

Kind code of ref document: A2